替格瑞洛联合阿司匹林治疗动脉粥样硬化性急性非严重缺血性卒中或TIA
在狭窄患者中,替格瑞洛联合阿司匹林较安慰剂联合阿司匹林显著降低30天卒中或死亡风险(8.1% vs 10.9%,HR 0.73,95%CI 0.56-0.96,P=0.023),NNT为34;无狭窄患者未见显著获益。
要点
- 同侧动脉粥样硬化性狭窄≥30%的患者30天卒中或死亡绝对风险更高,替格瑞洛联合阿司匹林绝对获益更大。
- 狭窄患者中替格瑞洛联合阿司匹林30天卒中或死亡风险HR 0.73,NNT=34。
- 无狭窄患者中联合治疗未显著降低主要终点,且严重出血风险显著增加(HR 5.87)。
核心结论
- 在非心源性非严重缺血性卒中或高危TIA患者中,替格瑞洛联合阿司匹林对同侧动脉粥样硬化性狭窄亚组未见治疗交互作用,但狭窄患者绝对风险更高且绝对风险降低更大。
研究设计与样本
- 患者接受替格瑞洛(首日180mg负荷,第2-30天90mg每日两次)或安慰剂,联合阿司匹林(首日300-325mg,第2-30天75-100mg每日一次)。
- 本分析为预设分析,比较同侧潜在因果性颈脑血管动脉粥样硬化性狭窄≥30%与无狭窄的患者。
主要发现
- 2351例(21.3%)存在同侧动脉粥样硬化性狭窄。
- 狭窄患者中,替格瑞洛组30天主要终点(卒中或死亡)发生92/1136(8.1%),安慰剂组132/1215(10.9%),HR 0.73(95%CI 0.56-0.96),P=0.023,NNT=34(95%CI 19-171)。
- 无狭窄患者中,替格瑞洛组主要终点发生211/4387(4.8%),安慰剂组230/4278(5.4%),HR 0.89(95%CI 0.74-1.08),P=0.23,交互作用P=0.245。
- 狭窄患者中,替格瑞洛组严重出血4例(0.4%),安慰剂组3例(0.2%),P=NS。
- 无狭窄患者中,替格瑞洛组严重出血24例(0.5%),安慰剂组4例(0.1%),HR 5.87(95%CI 2.04-16.9),P=0.001。
关键数值与推荐
- 同侧颈脑血管动脉粥样硬化性狭窄定义为≥30%。
- 主要终点为30天内卒中或死亡的时间。
- 狭窄患者中替格瑞洛联合阿司匹林较安慰剂联合阿司匹林显著降低30天卒中或死亡风险(HR 0.73,95%CI 0.56-0.96,P=0.023)。
- 狭窄患者中NNT为34(95%CI 19-171)。
- 无狭窄患者中严重出血风险显著增加(HR 5.87,95%CI 2.04-16.9,P=0.001)。
临床怎么用
- 对于急性非严重缺血性卒中或高危TIA且存在同侧颈脑血管动脉粥样硬化性狭窄≥30%的患者,可考虑替格瑞洛联合阿司匹林治疗30天以降低卒中或死亡风险。
- 治疗决策需权衡缺血获益与出血风险,尤其在无同侧狭窄的患者中严重出血风险显著增加。
局限性
- 本研究为探索性分析。
- 严重出血事件数较少,尤其在同侧狭窄亚组中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Among patients with a transient ischemic attack or minor ischemic strokes, those with ipsilateral atherosclerotic stenosis of cervicocranial vasculature have the highest risk of recurrent vascular events. METHODS: In the double-blind THALES (The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trial, we randomized patients with a noncardioembolic, nonsevere ischemic stroke, or high-risk transient ischemic attack to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30) within 24 hours of symptom onset. The present paper reports a prespecified analysis in patients with and without ipsilateral, potentially causal atherosclerotic stenosis ≥30% of cervicocranial vasculature. The primary end point was time to the occurrence of stroke or death within 30 days. RESULTS: Of 11 016 randomized patients, 2351 (21.3%) patients had an ipsilateral atherosclerotic stenosis. After 30 days, a primary end point occurred in 92/1136 (8.1%) patients with ipsilateral stenosis randomized to ticagrelor and in 132/1215 (10.9%) randomized to placebo (hazard ratio 0.73 [95% CI, 0.56-0.96], P=0.023) resulting in a number needed to treat of 34 (95% CI, 19-171). In patients without ipsilateral stenosis, the corresponding event rate was 211/4387 (4.8%) and 230/4278 (5.4%), respectively (hazard ratio, 0.89 [95% CI, 0.74-1.08]; P=0.23, Pinteraction=0.245). Severe bleeding occurred in 4 (0.4%) and 3 (0.2%) patients with ipsilateral atherosclerotic stenosis on ticagrelor and on placebo, respectively (P=NS), and in 24 (0.5%) and 4 (0.1%), respectively, in 8665 patients without ipsilateral stenosis (hazard ratio=5.87 [95% CI, 2.04-16.9], P=0.001). CONCLUSIONS: In this exploratory analysis comparing ticagrelor added to aspirin to aspirin alone, we found no treatment by ipsilateral atherosclerosis stenosis subgroup interaction but did identify a higher absolute risk and a greater absolute risk reduction of stroke or death at 30 days in patients with ipsilateral atherosclerosis stenosis than in those without. In this easily identified population, ticagrelor added to aspirin provided a clinically meaningful benefit with a number needed to treat of 34 (95% CI, 19-171). Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03354429.
引用
- Amarenco P, Denison H, Evans SR, et al. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020. PMID: 33198608. doi:10.1161/STROKEAHA.120.032239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。